Vigil Neuroscience (VIGL) Competitors

Olema Pharmaceuticals (NASDAQ:OLMA) and Vigil Neuroscience (NASDAQ:VIGL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, community ranking, profitability, earnings and risk.

Do institutionals and insiders hold more shares of OLMA or VIGL?

91.8% of Olema Pharmaceuticals shares are owned by institutional investors. Comparatively, 83.6% of Vigil Neuroscience shares are owned by institutional investors. 19.4% of Olema Pharmaceuticals shares are owned by insiders. Comparatively, 18.0% of Vigil Neuroscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Which has more volatility and risk, OLMA or VIGL?

Olema Pharmaceuticals has a beta of 2.1, indicating that its share price is 110% more volatile than the S&P 500. Comparatively, Vigil Neuroscience has a beta of 1.94, indicating that its share price is 94% more volatile than the S&P 500.

Do analysts prefer OLMA or VIGL?

Olema Pharmaceuticals presently has a consensus target price of $27.67, suggesting a potential upside of 423.00%. Vigil Neuroscience has a consensus target price of $16.25, suggesting a potential upside of 534.77%. Given Vigil Neuroscience's stronger consensus rating and higher probable upside, analysts plainly believe Vigil Neuroscience is more favorable than Olema Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olema Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Vigil Neuroscience	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.20

Does the media refer more to OLMA or VIGL?

In the previous week, Olema Pharmaceuticals had 1 more articles in the media than Vigil Neuroscience. MarketBeat recorded 6 mentions for Olema Pharmaceuticals and 5 mentions for Vigil Neuroscience. Vigil Neuroscience's average media sentiment score of 0.90 beat Olema Pharmaceuticals' score of 0.74 indicating that Vigil Neuroscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Olema Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vigil Neuroscience	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has preferable valuation and earnings, OLMA or VIGL?

Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Vigil Neuroscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Olema Pharmaceuticals	N/A	N/A	-$96.65M	-$2.21	-2.39
Vigil Neuroscience	N/A	N/A	-$82.64M	-$2.06	-1.24

Is OLMA or VIGL more profitable?

Olema Pharmaceuticals' return on equity of -53.56% beat Vigil Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Olema Pharmaceuticals	N/A	-53.56%	-47.86%
Vigil Neuroscience	N/A	-83.89%	-65.34%

Does the MarketBeat Community favor OLMA or VIGL?

Olema Pharmaceuticals received 3 more outperform votes than Vigil Neuroscience when rated by MarketBeat users. However, 85.00% of users gave Vigil Neuroscience an outperform vote while only 71.15% of users gave Olema Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Olema Pharmaceuticals	Outperform Votes 37 71.15%	Underperform Votes 15 28.85%
Vigil Neuroscience	Outperform Votes 34 85.00%	Underperform Votes 6 15.00%

Summary

Vigil Neuroscience beats Olema Pharmaceuticals on 9 of the 16 factors compared between the two stocks.